These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. Marginean EC; Melosky B Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791 [TBL] [Abstract][Full Text] [Related]
9. Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. Lee JJ; Chu E Clin Colorectal Cancer; 2018 Dec; 17(4):258-273. PubMed ID: 30072278 [TBL] [Abstract][Full Text] [Related]
11. Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers. Liu F; Zhong F; Wu H; Che K; Shi J; Wu N; Fu Y; Wang Y; Hu J; Qian X; Fan X; Wang W; Wei J Oncologist; 2023 Mar; 28(3):e136-e144. PubMed ID: 36724040 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Chu JN; Choi J; Ostvar S; Torchia JA; Reynolds KL; Tramontano A; Gainor JF; Chung DC; Clark JW; Hur C Cancer; 2019 Jan; 125(2):278-289. PubMed ID: 30343509 [TBL] [Abstract][Full Text] [Related]
13. Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy. Ghatalia P; Nagarathinam R; Cooper H; Geynisman DM; El-Deiry WS Cancer Biol Ther; 2017 Sep; 18(9):651-654. PubMed ID: 28726535 [TBL] [Abstract][Full Text] [Related]
14. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635 [TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022. André T; Cohen R; Salem ME Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834 [TBL] [Abstract][Full Text] [Related]
16. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches. Tan E; Sahin IH Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189 [No Abstract] [Full Text] [Related]
17. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702 [TBL] [Abstract][Full Text] [Related]
18. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a Gong J; Wang C; Lee PP; Chu P; Fakih M J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial. Coutzac C; Bibeau F; Ben Abdelghani M; Aparicio T; Cohen R; Coquan E; Dubreuil O; Evesque L; Ghiringhelli F; Kim S; Lesourd S; Neuzillet C; Phelip JM; Piessen G; Rochigneux P; Samalin E; Soularue E; Touchefeu Y; Tougeron D; Zaanan A; de la Fouchardière C Dig Liver Dis; 2022 Oct; 54(10):1335-1341. PubMed ID: 35907691 [TBL] [Abstract][Full Text] [Related]
20. Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade. Wang T; Lee LH; Vyas M; Zhang L; Ganesh K; Firat C; Segal NH; Desai A; Hechtman JF; Ntiamoah P; Weiser MR; Markowitz AJ; Vakiani E; Klimstra DS; Stadler ZK; Shia J Mod Pathol; 2019 Oct; 32(10):1551-1562. PubMed ID: 31175329 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]